Zhejiang Pharmaceutical Co., Ltd., founded in 1997, is a listed company and a large natural vitamin E manufacturer in China, mainly engaged in the production and operation of fat-soluble vitamins, quinolone antibiotics, anti-drug resistant antibiotics and other products
Zhejiang Pharmaceutical Co., Ltd. is a large-scale joint-stock integrated pharmaceutical enterprise established in May 1997. In August 1999, with the approval of the China Securities Regulatory Commission, the company publicly issued 58 million RMB A shares to the public, and in October of the same year, the company's shares were listed on the Shanghai Stock Exchange. By the end of 2015, the registered capital was 930 million yuan and the total assets were 8.2 billion yuan.
Zhejiang Pharmaceutical now has five major branches (subsidiaries) including Xinchang Pharmaceutical Factory, Vitamin Factory, Changhai Biological Branch, Zhejiang Laiyi Biotechnology Co., Ltd., Zhejiang Laiyi Pharmaceutical Co., Ltd., and two R&D units of Pharmaceutical Industry Research Institute and Shanghai Laiyi Biological Drug Research and Development Center. There are more than 6,000 employees, including more than 2,000 professional and technical personnel, accounting for more than 40% of the total number of employees.
At present, Zhejiang Medicine has formed a series of specialized and large-scale production of fat-soluble vitamins, vitaminoids, quinolone antibiotics, anti-drug resistant antibiotics and other products. The company's raw material products: the largest output of vitamin E in China, the second largest manufacturer in the world; The output of natural vitamin E is the largest in China and the third largest in the world; β-carotene and cantharidin are the largest suppliers in China and the third largest in the world; Vancomycin hydrochloride and teicoplanin have accounted for more than 40% of global production; The company's preparation products: levofloxacin lactate injection (trade name "Lebrixin") accounts for more than 20% of the national sales, vancomycin hydrochloride for injection (Lexin) accounts for more than 30% of the national sales, and teicoplanin for injection (Garicsson) is the largest supplier in China.
Through the careful implementation of the development strategy of "innovation and entrepreneurship, competitive development, science and technology development, and talent strengthening", Zhejiang Medicine firmly grasps the main line of product development, highlights structural adjustment, integrates various resources, strengthens original technological innovation and technological innovation of advantageous products, does a good job in DMF file registration and FDA certification of advantageous varieties, vigorously promotes cleaner production and circular economy, takes globalization as a foothold, builds a perfect market network, establishes a good brand image, and creates an advanced corporate culture. At present, Zhejiang Medicine has developed into a pharmaceutical enterprise with advanced technology, large scale, strong strength and influence on the global market.
